Lexapro Articles
Forest Labs' profit slumps 76% on Lexapro patent loss
23 April 2013
Forest Labs, Gedeon Richter plan 2012 filing for cariprazine
29 February 2012
Lundbeck partner Mochida files for escitalopram approval in Japan
17 September 2010
Generic erosion of atypical antipsychotics will cause the bipolar disorder drug market to decline by over $1 billion through 2018
6 November 2009
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
21 October 2009
Zacks analysts view AstraZeneca/Forest deal favorably
18 August 2009
Patent protection for key blockbuster depression drugs will drive growth in Europe and Japan, but not USA, says DR report
18 August 2009
Lundbeck shares driven up by higher profit
15 May 2009
US Lipitor and Lexapro cost cut by pill splitting
14 April 2009
Lundbeck's 2008 net profit drops 15%
16 March 2009
Forest accused of illegal promotion
9 March 2009
Lexapro and Zoloft are "best" antidepressants
9 February 2009
Lundbeck's 3rd-qtr 2008 net profit drops 11%
24 November 2008
Almirall tumbles 42% as COPD drug disappoints
15 September 2008
Lundbeck profit down 52% on Flurizan failure
1 September 2008
Forest's EPS falls to $0.79 in 2nd-qtr 2008
4 August 2008
FDA clears Lupin's escitalopram oxalate
23 June 2008
Forest to apply for Lexapro in adolscents
19 May 2008
Forest Labs swings back to profit in fiscal 1st-qtr
21 April 2008
Lundbeck's EPS up 65%; shares fall on CEO exit
17 March 2008
Stock Commentary - New York week to Jan 21, 2008
28 January 2008
Lexapro and Namenda help Forest's income for fiscal 3rd-qtr soar 21%, beating estimates
21 January 2008
Lundbeck's 3rd-qtr net profit soars 67%
3 December 2007
Forest's EPS drops 5% on Microbia charge
29 October 2007
US Apeals Court upholds Lexapro patent decision
10 September 2007
Lundbeck's 2nd-qtr 2007 revenue increases 19%
3 September 2007
Forest's income for fiscal 1st qtr soars 34%
23 July 2007
SSRIs lower BMD in men and women
2 July 2007
Forest records $238M loss for fiscal 4th-qtr
7 May 2007
H Lundbeck's profit drops 30% for 2006
26 March 2007
US FDA warns about misrepresented drugs bought over the Internet
26 February 2007
Forest Labs 4th-qtr profit jumps 28%
29 January 2007
Patent expiries will stem growth of antidepressants market
18 December 2006
H Lundbeck's 3rd-qtr net profit up 3%
27 November 2006
Stock Commentary - New York week to Oct 23, 2006
30 October 2006
H Lundbeck' 2nd-qtr profits fall 69%
28 August 2006
Stock Commentary - New York week to July 24, 2006
24 July 2006
Forest Lab's 1st-qtr net revenues leap 15%
24 July 2006
Final US approval for Teva's generic Lexapro
29 May 2006
Cymbalta: less impact on sex than Lexapro
29 May 2006
H Lundbeck's 1st-qtr 2006 profit drops 29%
22 May 2006
H Lundbeck's 2005 net profits down 6%
27 March 2006
Stock Commentary - New York week to Aug 15
5 September 2005
US FDA posts DSOB meeting summary
15 August 2005
EMEA warning over SSRIs, SNRIs in children
26 April 2005
Forest Labs' sales hit by Celexa competition
25 April 2005
Stock Commentary - New York
18 April 2005
US FDA rejects Forest's Lexapro for anxiety
11 April 2005
Forest Labs cuts earnings forecast
11 April 2005
Forest hit with second appro letter for Lexapro
7 March 2005
Forest disappoints, despite 17% EPS hike
24 January 2005
Forest beats 2nd-qtr targets; raises outlook
25 October 2004
Stock Commentary - New York week to Oct 4
11 October 2004
Forest raises fiscal 2005 2nd-qtr earnings estimate
11 October 2004
Forest pursues new use for Lexapro
6 September 2004
IVAX response to Australia patent news
30 August 2004
Lundbeck net up 46%
23 August 2004
Forest's Lexapro fails pediatric efficacy trial
5 July 2004
Forest posts 20% jump in fiscal-2003 sales
3 May 2004
Lexapro as effective as Paxil for GAD
22 March 2004
Forest profit boosted by antidepressants
26 January 2004
Lexapro cleared for new use by FDA
5 January 2004
Positive new data for Forest's Lexapro
22 December 2003
Stock Commentary - New York
22 December 2003
Lundbeck issues profit warning; shares slump on antidepressant woes
10 November 2003
Forest's earnings lifted by antidepressants
20 October 2003
Stock Commentary - New York
6 October 2003
US approvable letter for Forest's Lexapro in GAD
6 October 2003
Forest's Lexapro "has benefit over Effexor"
29 September 2003
Forest's Lexapro "has benefit over Effexor"
29 September 2003
Forest/Lundbeck file suit against IVAX
29 September 2003
IVAX applies to FDA for generic Lexapro
18 August 2003
Lexapro offsets Celexa for Forest's 2nd-qtr
21 July 2003
Forest seeks approval for Lexapro in panic
12 May 2003
Antidepressant sales boost Forest in 4th qtr
28 April 2003
Antidepressants drive Forest's profits upward
27 January 2003
Forest Labs raises earnings estimate
6 January 2003
Forest's lercanidipine approvable, says FDA
12 August 2002
Lundbeck buys into Brazilian market
10 June 2002
Forest Lab's Lexapro approvable in USA
3 June 2002
Celexa drives growth at Forest Labs
6 May 2002
Showing 1-99 of 99 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
